Lilly Mark

2.2k total citations
19 papers, 1.4k citations indexed

About

Lilly Mark is a scholar working on Molecular Biology, Infectious Diseases and Pharmacology. According to data from OpenAlex, Lilly Mark has authored 19 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Infectious Diseases and 5 papers in Pharmacology. Recurrent topics in Lilly Mark's work include Antimicrobial Resistance in Staphylococcus (6 papers), Pain Mechanisms and Treatments (5 papers) and Neuroscience and Neuropharmacology Research (3 papers). Lilly Mark is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (6 papers), Pain Mechanisms and Treatments (5 papers) and Neuroscience and Neuropharmacology Research (3 papers). Lilly Mark collaborates with scholars based in United States, Canada and Bulgaria. Lilly Mark's co-authors include James Harrison, Garth T. Whiteside, Katharine Walker, Kenneth J. Valenzano, Michelle Pearson, Susan L. Gottshall, James D. Pomonis, Jamie Boulet, Malvika Kaul and Edmond J. LaVoie and has published in prestigious journals such as Neuroscience, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Lilly Mark

19 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lilly Mark United States	15	566	504	451	438	203	19	1.4k
Zaijie Jim Wang United States	28	218 0.4×	772 1.5×	468 1.0×	571 1.3×	69 0.3×	63	1.8k
Matthew W. Buczynski United States	21	671 1.2×	390 0.8×	485 1.1×	792 1.8×	79 0.4×	37	2.2k
Janice Oyarzo United States	18	219 0.4×	413 0.8×	119 0.3×	260 0.6×	22 0.1×	24	1.3k
L. Bartolini Italy	16	329 0.6×	243 0.5×	451 1.0×	406 0.9×	131 0.6×	29	1.3k
Dennis K. Miller United States	25	205 0.4×	288 0.6×	885 2.0×	1.2k 2.6×	21 0.1×	76	2.2k
Mireille Alhouayek Belgium	25	915 1.6×	415 0.8×	186 0.4×	711 1.6×	16 0.1×	52	2.2k
Luigi Maiolino Italy	22	125 0.2×	283 0.6×	54 0.1×	415 0.9×	262 1.3×	60	1.5k
Govindhasamy Pushpavathi Selvakumar United States	26	115 0.2×	418 0.8×	233 0.5×	642 1.5×	91 0.4×	45	2.0k
William A. Eimer United States	13	425 0.8×	1.9k 3.9×	472 1.0×	1.1k 2.5×	42 0.2×	19	2.9k
Rodrigo Portes Ureshino Brazil	22	138 0.2×	250 0.5×	190 0.4×	401 0.9×	75 0.4×	44	1.3k

Countries citing papers authored by Lilly Mark

Since Specialization

Citations

This map shows the geographic impact of Lilly Mark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lilly Mark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lilly Mark more than expected).

Fields of papers citing papers by Lilly Mark

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lilly Mark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lilly Mark. The network helps show where Lilly Mark may publish in the future.

Co-authorship network of co-authors of Lilly Mark

This figure shows the co-authorship network connecting the top 25 collaborators of Lilly Mark. A scholar is included among the top collaborators of Lilly Mark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lilly Mark. Lilly Mark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Chen, Kuan‐Ju, Yuchen Zhou, Lilly Mark, et al.. (2023). The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species. Frontiers in Pharmacology. 14. 1208780–1208780. 7 indexed citations

Fujita, Junso, Lilly Mark, Malvika Kaul, et al.. (2023). Structural and Antibacterial Characterization of a New Benzamide FtsZ Inhibitor with Superior Bactericidal Activity and In Vivo Efficacy Against Multidrug-Resistant Staphylococcus aureus. ACS Chemical Biology. 18(3). 629–642. 10 indexed citations

Kaul, Malvika, et al.. (2022). Combination with a FtsZ inhibitor potentiates the in vivo efficacy of oxacillin against methicillin-resistant Staphylococcus aureus. Medicinal Chemistry Research. 31(10). 1705–1715. 7 indexed citations

Kaul, Malvika, Lilly Mark, Ajit K. Parhi, Edmond J. LaVoie, & Daniel S. Pilch. (2016). Combining the FtsZ-Targeting Prodrug TXA709 and the Cephalosporin Cefdinir Confers Synergy and Reduces the Frequency of Resistance in Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 60(7). 4290–4296. 41 indexed citations

Kaul, Malvika, Lilly Mark, Ajit K. Parhi, et al.. (2015). TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 59(8). 4845–4855. 99 indexed citations

Kaul, Malvika, et al.. (2013). Pharmacokinetics and in vivo antistaphylococcal efficacy of TXY541, a 1-methylpiperidine-4-carboxamide prodrug of PC190723. Biochemical Pharmacology. 86(12). 1699–1707. 44 indexed citations

Kaul, Malvika, et al.. (2013). An FtsZ-Targeting Prodrug with Oral Antistaphylococcal Efficacy In Vivo. Antimicrobial Agents and Chemotherapy. 57(12). 5860–5869. 53 indexed citations

O’Neill, David J., Adedayo Adedoyin, Jenifer A. Bray, et al.. (2011). Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152). Journal of Medicinal Chemistry. 54(19). 6824–6831. 8 indexed citations

Chanda, Pranab K., Ying Gao, Lilly Mark, et al.. (2010). Monoacylglycerol Lipase Activity Is a Critical Modulator of the Tone and Integrity of the Endocannabinoid System. Molecular Pharmacology. 78(6). 996–1003. 182 indexed citations

10.

Strassle, Brian W., Lilly Mark, Liza Leventhal, et al.. (2010). Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease. Osteoarthritis and Cartilage. 18(10). 1319–1328. 108 indexed citations

11.

Hummel, Michele, Terri Cummons, Peimin Lu, et al.. (2010). Pain is a salient “stressor” that is mediated by corticotropin-releasing factor-1 receptors. Neuropharmacology. 59(3). 160–166. 39 indexed citations

12.

Zhang, Puwen, Eugene A. Terefenko, Jenifer A. Bray, et al.. (2009). 1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: Potent, Selective, and Orally Efficacious Norepinephrine Reuptake Inhibitors. Journal of Medicinal Chemistry. 52(18). 5703–5711. 20 indexed citations

13.

Engler, Harald, Xiaoping Zhou, Lilly Mark, et al.. (2007). Small interfering RNA-mediated selective knockdown of NaV1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats. Neuroscience. 146(2). 812–821. 101 indexed citations

14.

Ilyin, Victor I., James D. Pomonis, Garth T. Whiteside, et al.. (2006). Pharmacology of 2-[4-(4-Chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: A Potent, Broad-Spectrum State-Dependent Sodium Channel Blocker for Treating Pain States. Journal of Pharmacology and Experimental Therapeutics. 318(3). 1083–1093. 27 indexed citations

15.

Whiteside, Garth T., Susan L. Gottshall, Jamie Boulet, et al.. (2005). A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. European Journal of Pharmacology. 528(1-3). 65–72. 75 indexed citations

16.

Valenzano, Kenneth J., Laykea Tafesse, Gary Lee, et al.. (2005). Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology. 48(5). 658–672. 233 indexed citations

17.

Whiteside, Garth T., James Harrison, Jamie Boulet, et al.. (2004). Pharmacological characterisation of a rat model of incisional pain. British Journal of Pharmacology. 141(1). 85–91. 137 indexed citations

18.

Whiteside, Garth T., James Harrison, Michelle Pearson, et al.. (2004). DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic Acid), a Novel, Systemically Available, and Peripherally Restricted Mu Opioid Agonist with Antihyperalgesic Activity: II. In Vivo Pharmacological Characterization in the Rat. Journal of Pharmacology and Experimental Therapeutics. 310(2). 793–799. 21 indexed citations

19.

Pomonis, James D., et al.. (2003). N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2 H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: II. In Vivo Characterization in Rat Models of Inflammatory and Neuropathic Pain. Journal of Pharmacology and Experimental Therapeutics. 306(1). 387–393. 213 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact